Drug intelligence / Profile preview

TQ-B3456

Development stage: Discontinued
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral (tablet)

Overview

TQ-B3456 is a small molecule antineoplastic drug developed by Chia Tai Tianqing Pharmaceutical Group. It was investigated as an oral therapy for cancer, specifically non-small cell lung cancer (NSCLC), including metastatic disease in second-line or greater settings. The drug acts as an antagonist of the epidermal growth factor receptor (EGFR), targeting the EGFR/erbB1 pathway, which is implicated in tumor growth and progression. Clinical development reached phase 1 trials but was terminated before further advancement[1][2][4][5].

Other names: TQB3456TQB-3456TQB 3456TQ B3456TQ-B3456TQ-B-3456TQ-B 3456

Targets

EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on TQ-B3456.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TQ-B3456.

Explore the full profile